期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 67, 期 3, 页码 779-794出版社
IOS PRESS
DOI: 10.3233/JAD-180766
关键词
Alzheimer's disease; cholinesterase inhibitor; dementia; disease-modifying; memantine; symptomatic; treatment combination
资金
- Lundbeck
- COBRE NIH/MIGMS [P20GM109025]
- Keep Memory Alive
Although Alzheimer's disease (AD) is the world's leading cause of dementia and the population of patients with AD continues to grow, no new therapies have been approved in more than a decade. Many clinical trials of single-agent therapies have failed to affect disease progression or symptoms compared with placebo. The complex pathophysiology of AD may necessitate combination treatments rather than monotherapy. The goal of this narrative literature review is to describe types of combination therapy, review the current clinical evidence for combination therapy regimens (both symptomatic and disease-modifying) in the treatment of AD, describe innovative clinical trial study designs that may be effective in testing combination therapy, and discuss the regulatory and drug development landscape for combination therapy. Successful combination therapies in other complex disorders, such as human immunodeficiency virus, may provide useful examples of a potential path forward for AD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据